What Did You Miss at the 3rd Spatial Biology for Drug Development Summit
Spatial biology is at a turning point. Rapid advances in resolution, sensitivity, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin, highlight the strong momentum and confidence building across the sector. Yet, challenges around data standardization, integration, scalability, and cost continue to limit widespread adoption, particularly among small and mid-sized biopharma companies.
The 3rd Spatial Biology for Drug Development Summit was your opportunity to come together with industry experts to address these barriers head-on. The 2025 meeting connected leading biopharma, technology providers, and thought leaders to share practical examples, proven strategies, and clear value stories that demonstrate how spatial biology can deliver return on investment across discovery, translational research, and clinical development.
Top 5 Takeaways from 2025:
Discover unprecedented insights into the tumor microenvironment with spatial transcriptomics to reveal novel biomarkers and fuel your therapeutic pipeline
Tackle reproducibility and standardization barriers to advance and scale spatial biology from early discovery to real-world impact — accelerating robust, industry-wide adoption
Leverage advanced computational pipelines to process complex spatial data at scale, delivering deeper insights into tissue architecture for novel breakthroughs
Enable scalable, integrated data infrastructure to ensure spatial biology is fully interoperable across teams and platforms to save time in your clinical trials
Unlock smarter spatial biology partnerships to maximize ROI, scale breakthroughs, and bring better treatments to patients faster
What Your Peers Had to Say:
“The meeting was well organized. Relevant information was provided. Important contributors to spatial biology field attended the meeting including solution providers, academia and industry leaders.”
Past Attendee, Associate Director – Computational Biology
Takeda
“The event was well organized, attended and catered. The venue was very pleasant and appropriate to the size of the event. The structure allowed for meaningful discussion and networking.”
Past Attendee, Senior Scientist
AbbVie